Galmed Pharmaceuticals (GLMD) Total Non-Current Liabilities (2013 - 2025)
Galmed Pharmaceuticals (GLMD) posted quarterly Total Non-Current Liabilities of $21.6 million for Q3 2025, down 5.94% quarter-over-quarter from $22.9 million in Q2 2025.
Galmed Pharmaceuticals (GLMD) Total Non-Current Liabilities (2013 - 2025) Analysis & Trends
Galmed Pharmaceuticals' Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $21.6 million for Q3 2025.
- In Q3 2025, Total Non-Current Liabilities changed N/A year-over-year to $21.6 million; the TTM figure through Sep 2025 stood at $21.6 million (changed N/A YoY), while the FY2024 annual figure was $1.7 million, up 165.13% from the prior year.
- Total Non-Current Liabilities for Q3 2025 stood at $21.6 million, down from $22.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $22.9 million in Q2 2025, with the low at $44000.0 in Q4 2022.
- The 5-year median for Total Non-Current Liabilities is $283000.0 (2021), against an average of $4.1 million.
- The sharpest annual moves came in 2021 and 2023: Total Non-Current Liabilities slumped 99.89% in 2021, then jumped 2665.57% in 2023.
- Galmed Pharmaceuticals' Total Non-Current Liabilities stood at $229000.0 in 2021, then tumbled by 80.79% to $44000.0 in 2022, then surged by 1327.27% to $628000.0 in 2023, then soared by 165.13% to $1.7 million in 2024, then surged by 1194.41% to $21.6 million in 2025.
- Business Quant data shows GLMD's Total Non-Current Liabilities at $21.6 million in Q3 2025, $22.9 million in Q2 2025, and $1.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 9.32 Bn |
| 10 | Galmed Pharmaceuticals | 2.36 Mn | -9.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 21.55 Mn |
| Jun 30, 2025 | 22.91 Mn |
| Dec 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | 628,000.00 |
| Mar 31, 2023 | 5.06 Mn |
| Dec 31, 2022 | 44,000.00 |
| Sep 30, 2022 | 89,000.00 |
| Jun 30, 2022 | 134,000.00 |
| Mar 31, 2022 | 183,000.00 |
| Dec 31, 2021 | 229,000.00 |
| Sep 30, 2021 | 274,000.00 |
| Jun 30, 2021 | 318,000.00 |
| Mar 31, 2021 | 283,000.00 |
| Dec 31, 2020 | 216.00 Mn |
| Sep 30, 2020 | 247,000.00 |
| Jun 30, 2020 | 251,000.00 |
| Mar 31, 2020 | 302,000.00 |
| Dec 31, 2019 | 352,000.00 |
| Sep 30, 2019 | 389,000.00 |
| Jun 30, 2019 | 442,000.00 |